产品名称 | NebuSelect™ Recombinant Human Kallikrein 5/KLK5, His-tag |
---|---|
目录号 | NBL-242398 |
别名 | Kallikrein 5/KLK5; Kallikrein c; Klnc; KLK5; KLKL2; KLK-L2; SCTE |
外观 | see COA |
分子量 | |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | Q9Y337 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-242398-100ug | 100ug | Inquire | Inquire | |
NBL-242398-1mg | 1mg | Inquire | Inquire | |
NBL-242398-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human Kallikrein 5/KLK5, His-tag
Catalog#:
NBL-242398
Description:
NebuSelect™ Recombinant Human Kallikrein 5/KLK5, His-tag(Cat#NBL-242398) is expressed in HEK293 with His tag at the C-Terminus.It contains Val23-Ser293.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 30.7 kDa. Due to glycosylation, the protein migrates to 42-48 kDa based on Bis-Tris PAGE result.
Target Name:
Kallikrein 5/KLK5; Kallikrein c; Klnc; KLK5; KLKL2; KLK-L2; SCTE
Target Information:
The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches.
Amino Acid Sequence:
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.